Tom van den Ende

1.1k total citations
27 papers, 512 citations indexed

About

Tom van den Ende is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tom van den Ende has authored 27 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Surgery and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tom van den Ende's work include Gastric Cancer Management and Outcomes (10 papers), Esophageal Cancer Research and Treatment (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Tom van den Ende is often cited by papers focused on Gastric Cancer Management and Outcomes (10 papers), Esophageal Cancer Research and Treatment (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Tom van den Ende collaborates with scholars based in Netherlands, United Kingdom and China. Tom van den Ende's co-authors include Hanneke W.M. van Laarhoven, Sandra Salm, Anne‐Fleur van Rootselaar, Martijn G.H. van Oijen, Sarvi Sharifi, Maarten F. Bijlsma, Sarah Derks, Maarten C.C.M. Hulshof, JanWillem Duitman and C. Arnold Spek and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tom van den Ende

27 papers receiving 507 citations

Peers

Tom van den Ende

PRM

ONCOL

SURGE

NEURO

Calvin Lee United States

Kee Hwan Kwon South Korea

Hideaki Naoe Japan

Erin N. McComb United States

Anjela Tzontcheva United States

Wenqing Jiang China

Jaime Vengoechea United States

Chisa Aoyama United States

Stéphanie Henry Belgium

Silvia D’Amico Italy

Calvin Lee United States

Tom van den Ende

60 ×0.4

PRM

209 ×1.3

ONCOL

135 ×1.1

SURGE

44 ×0.4

43 ×0.5

NEURO

Citations per year, relative to Tom van den Ende Tom van den Ende (= 1×) peers Calvin Lee

Countries citing papers authored by Tom van den Ende

Since Specialization

Citations

This map shows the geographic impact of Tom van den Ende's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom van den Ende with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom van den Ende more than expected).

Fields of papers citing papers by Tom van den Ende

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom van den Ende. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom van den Ende. The network helps show where Tom van den Ende may publish in the future.

Co-authorship network of co-authors of Tom van den Ende

This figure shows the co-authorship network connecting the top 25 collaborators of Tom van den Ende. A scholar is included among the top collaborators of Tom van den Ende based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom van den Ende. Tom van den Ende is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Li‐Ting, Myrthe Jager, Tom van den Ende, et al.. (2025). Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling. Genome Research. 35(4). 886–899. 3 indexed citations

Ende, Tom van den, et al.. (2025). Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review. Cancer Treatment Reviews. 140. 103025–103025. 5 indexed citations

Ende, Tom van den, Nicolien C. de Clercq, Mark Davids, et al.. (2024). Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort. JNCI Journal of the National Cancer Institute. 116(11). 1834–1844. 3 indexed citations

Ende, Tom van den, Floris H. P. van Velden, Henry C. Woodruff, et al.. (2024). Integrating Clinical Variables, Radiomics, and Tumor-derived Cell-Free DNA for Enhanced Prediction of Resectable Esophageal Adenocarcinoma Outcomes. International Journal of Radiation Oncology*Biology*Physics. 121(4). 963–974. 2 indexed citations

Ende, Tom van den, Ymke van der Pol, Aafke Creemers, et al.. (2023). Genome‐wide and panel‐based cell‐free DNA characterization of patients with resectable esophageal adenocarcinoma. The Journal of Pathology. 261(3). 286–297. 3 indexed citations

Nie, Run‐Cong, Fo‐Ping Chen, Mariano Provencio, et al.. (2023). Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. European Journal of Cancer. 186. 211–221. 11 indexed citations

Moldován, Norbert, Ymke van der Pol, Tom van den Ende, et al.. (2023). Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis. Cell Reports Medicine. 5(1). 101349–101349. 26 indexed citations

Ende, Tom van den, Floris H. P. van Velden, Henry C. Woodruff, et al.. (2023). Outcome prediction in resectable esophageal adenocarcinoma based on clinical variables, radiomics, and ctDNA.. Journal of Clinical Oncology. 41(4_suppl). 423–423. 2 indexed citations

Nie, Run‐Cong, Fo‐Ping Chen, Mariano Provencio, et al.. (2023). Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Pooled Analysis of 29 Clinical Trials. SSRN Electronic Journal. 4 indexed citations

10.

Han, Dingpei, Yichao Han, Wei Guo, et al.. (2023). High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy. Journal for ImmunoTherapy of Cancer. 11(11). e007847–e007847. 18 indexed citations

11.

Velzen, M.J.M. van, Aafke Creemers, Tom van den Ende, et al.. (2022). Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. Gastric Cancer. 25(5). 906–915. 17 indexed citations

12.

Clercq, Nicolien C. de, Tom van den Ende, Andrei Prodan, et al.. (2021). Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study. Clinical Cancer Research. 27(13). 3784–3792. 54 indexed citations

13.

Ende, Tom van den, et al.. (2021). A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. Cancer Treatment Reviews. 99. 102249–102249. 8 indexed citations

14.

Ende, Tom van den, Héctor G. van den Boorn, Faridi S. van Etten‐Jamaludin, et al.. (2020). Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1874(1). 188386–188386. 73 indexed citations

15.

Ende, Tom van den, Héctor G. van den Boorn, Emil ter Veer, et al.. (2019). COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 9. 684–684. 11 indexed citations

16.

Ende, Tom van den, Emil ter Veer, Suzanne S. Gisbertz, et al.. (2019). The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers. 11(1). 80–80. 33 indexed citations

17.

Ende, Tom van den, Emil ter Veer, Mark I. van Berge Henegouwen, et al.. (2019). Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers. 11(4). 530–530. 20 indexed citations

18.

Veer, Emil ter, et al.. (2018). Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncologica. 57(12). 1599–1604. 11 indexed citations

19.

Ende, Tom van den, Elizabeth Smyth, Maarten C.C.M. Hulshof, & Hanneke W.M. van Laarhoven. (2018). Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. Best Practice & Research Clinical Gastroenterology. 36-37. 45–52. 11 indexed citations

20.

Ende, Tom van den, Sarvi Sharifi, Sandra Salm, & Anne‐Fleur van Rootselaar. (2017). Familial Cortical Myoclonic Tremor and Epilepsy, an Enigmatic Disorder: From Phenotypes to Pathophysiology and Genetics. A Systematic Review. PubMed. 8. 503–503. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact